AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer | BMC Cancer | Full Text

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer | BMC Cancer | Full Text

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

Immune checkpoint inhibitors (ICIs) reported remarkable achievements in several solid tumours. However, in metastatic colorectal cancer (mCRC) promising results are limited to patients with deficient mismatch ...

Authors:Carlotta Antoniotti, Beatrice Borelli, Daniele Rossini, Filippo Pietrantonio, Federica Morano, Lisa Salvatore, Sara Lonardi, Federica Marmorino, Stefano Tamberi, Salvatore Corallo, Giampaolo Tortora, Francesca Bergamo, Di Stefano Brunella, Alessandra Boccaccino, Elisa Grassi, Patrizia Racca…

Citation:BMC Cancer 2020 20:683

Content type:Study protocol

 

Published on: 22 July 2020

• ViewFull Text
 
• ViewPDF